REGN - Regeneron Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
324.21
+8.04 (+2.54%)
As of 12:06PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close316.17
Open318.08
Bid323.77 x 100
Ask324.14 x 100
Day's Range316.24 - 327.16
52 Week Range310.51 - 543.55
Volume313,664
Avg. Volume956,825
Market Cap34.884B
Beta1.56
PE Ratio (TTM)31.36
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Oakmark fund manager talks his Q1 buys
    CNBC Videos14 days ago

    Oakmark fund manager talks his Q1 buys

    Bill Nygren, Oakmark Fund portfolio manager, discusses his views on the market and his value stock picks.

  • Analysts’ Recommendations for Exelixis in April 2018
    Market Realist7 days ago

    Analysts’ Recommendations for Exelixis in April 2018

    In February 2018, Exelixis (EXEL) and its partner Daiichi Sankyo announced that it had submitted a regulatory application for esaxerenone therapy to the Japanese Pharmaceutical and Medical Devices Agency for the treatment of individuals with hypertension. According to the prior agreement between Exelixis and Daiichi Sankyo, Exelixis is set to receive a milestone payment of $20 million from Daiichi Sankyo. Daiichi Sankyo’s regulatory application has been supported by the results of Phase 3 trials evaluating the safety and efficacy of esaxerenone in individuals with essential hypertension compared to eplerenone.

  • InvestorPlace9 days ago

    AbbVie Inc. Is a Clear Value Play in Biotech Stocks

    Since topping over $120 a share three distinct times since February, shares of AbbVie Inc. (NYSE:ABBV) are still down around 25 percent. Whether the stock was perfectly priced or investors wanted an excuse to lock in profits, ABBV stock still has tremendous value and growth ahead. On March 22, AbbVie reported disappointing Phase 2 data for its Rova-T study that sent its shares lower.

  • Upadacitinib Could Drive AbbVie’s Long-Term Growth
    Market Realist10 days ago

    Upadacitinib Could Drive AbbVie’s Long-Term Growth

    In April 2018, AbbVie (ABBV) positive results for its Phase 3 SELECT-COMPARE trial, which evaluated the safety and efficacy of upadacitinib for adults with moderate-to-severe rheumatoid arthritis. The trial met its primary endpoint of improved ACR201 scores and clinical remission.

  • Exploring the Growth of Regeneron’s Praluent
    Market Realist14 days ago

    Exploring the Growth of Regeneron’s Praluent

    Regeneron Pharmaceuticals’ (REGN) Praluent is marketed in the United States as an adjunct to diet and maximally tolerated statin therapy for treating adults with heterozygous familial hypercholesterolemia (or HeFH) or clinical atherosclerotic cardiovascular disease (or ASCVD). Praluent is also marketed in Japan and some countries in the European Union. Praluent is a fully human monoclonal antibody inhibitor of PCSK9.

  • Investopedia14 days ago

    3 Biotech Stocks Analysts Have Been Too Bullish On

    Regeneron, Incyte and Tesaro have all had a terrible start to 2018, with shares down 14% or more.

  • Barrons.com15 days ago

    Vertex Is Worth More Than You Think

    Shares of  Vertex Pharmaceuticals (VRTX) have easily outrun the market year-to-date, rising 8%, and the drug maker has notched returns of more than 42% in the past year. Analyst Hartaj Singh reiterated an Outperform rating and $190 price target on the shares Wednesday, but notes that Vertex could see as much as 50% upside to that target, which would put the shares at $285.

  • FDA Restricts Sale of Bayer's Essure Birth Control Device
    Zacks16 days ago

    FDA Restricts Sale of Bayer's Essure Birth Control Device

    FDA puts restriction on the sale of Bayer's (BAYRY) implanted birth control device Essure.

  • Thomson Reuters StreetEvents16 days ago

    Edited Transcript of REGN presentation 6-Mar-17 6:05pm GMT

    Regeneron Pharmaceuticals Inc at Raymond James Institutional Investors Conference

  • FDA Okays Label Expansion of Pacira's Exparel's, Stock Up
    Zacks17 days ago

    FDA Okays Label Expansion of Pacira's Exparel's, Stock Up

    Shares of Pacira (PCRX) jump by about 12.9% after its drug Exparel gets approval by the FDA for an expanded indication.

  • Emergent (EBS) Gains 86.1% in a Year's Time: Here's Why
    Zacks20 days ago

    Emergent (EBS) Gains 86.1% in a Year's Time: Here's Why

    Let us look at the factors that have led to the increase in share price of Emergent (EBS).

  • Novo Nordisk Obtains Licence for Sickle Cell Disease Program
    Zacks20 days ago

    Novo Nordisk Obtains Licence for Sickle Cell Disease Program

    Novo Nordisk (NVO) secures a global licence for United States' biotech company EpiDestiny's sickle cell disease program EPI01.

  • Catalyst (CPRX) Up on New Drug Application for Firdapse
    Zacks21 days ago

    Catalyst (CPRX) Up on New Drug Application for Firdapse

    Catalyst (CPRX) new drug application for its lead pipeline candidate keeps it on a growth trajectory.

  • Bio-Path Leukemia Combo Study Shows Positive Early Data
    Zacks22 days ago

    Bio-Path Leukemia Combo Study Shows Positive Early Data

    Bio-Path (BPTH) announces positive interim data from phase II study of its lead pipeline candidate ??? prexigebersen ??? in combination with low-dose cytarabine (LDAC) for leukemia patients.

  • Biotech Stock Roundup: EDGE Falls, ALKS Down, FDA OK's AMGN Drug Label Expansion
    Zacks22 days ago

    Biotech Stock Roundup: EDGE Falls, ALKS Down, FDA OK's AMGN Drug Label Expansion

    The biotech sector grabbed headlines last week as Edge Therapeutics crashed on news of discontinuation of its phase III study while Amgen's Blincyto got FDA's nod for label expansion.

  • Rigel (RIGL) Sinks on Failure of Mid-Stage Study on Lead Drug
    Zacks22 days ago

    Rigel (RIGL) Sinks on Failure of Mid-Stage Study on Lead Drug

    Rigel's (RIGL) stock plunges 13% on the failure of a phase II study on lead drug, fostamatinib, in patients with IgA nephropathy (IgAN).

  • Sanofi's (SNY) Skin Cancer Candidate Filing Accepted in EU
    Zacks23 days ago

    Sanofi's (SNY) Skin Cancer Candidate Filing Accepted in EU

    Sanofi's (SNY) filing for its antibody cemiplimab for skin cancer and the label expansion of its marketed drug Dupixent for asthama wins acceptance from EMA.

  • Alkermes Sinks as FDA Refuses Depression Drug Review
    Zacks23 days ago

    Alkermes Sinks as FDA Refuses Depression Drug Review

    Alkermes (ALKS) shares declined by more than 21% as it received a Refusal to File letter from the FDA for its pipeline candidate, ALKS 5461, which was developed for major depressive disorder (MDD).

  • Why Did Regeneron Pharmaceuticals’ Stock Price Rise Last Week?
    Market Realist23 days ago

    Why Did Regeneron Pharmaceuticals’ Stock Price Rise Last Week?

    On March 28, 2018, Regeneron Pharmaceuticals (REGN) was trading at $344.36, a ~9.8% rise from its 52-week low of $313.53. On March 29, Regeneron stock closed at $344.36, which represented a ~7.2% rise from its share price in the week ended March 23, 2017. On March 21, 2018, Regeneron Pharmaceuticals announced a collaboration agreement with Alnylam Pharmaceuticals (ALNY) for the identification of RNA interference therapeutics for the treatment of chronic liver disease NASH (non-alcoholic steatohepatitis) and other related diseases.

  • Celgene (CELG) President and COO to Step Down: What's Ahead?
    Zacks23 days ago

    Celgene (CELG) President and COO to Step Down: What's Ahead?

    Celgene's (CELG) president and chief operating officer, Scott A. Smith, has decided to step down from his position with immediate effect further adding to the company's woes.

  • EMA Accepts Regeneron/Sanofi's application for Dupixent
    Zacks23 days ago

    EMA Accepts Regeneron/Sanofi's application for Dupixent

    Regeneron and partner Sanofi's application for the label expansion of Dupixent has been accepted by the regulatory body in Europe. The application is also under review in the United States.

  • Amgen's (AMGN) Xgeva Gets EU Approval for Expanded Label
    Zacks23 days ago

    Amgen's (AMGN) Xgeva Gets EU Approval for Expanded Label

    Amgen (AMGN) gets EU approval to expand the label of its key drug, Xgeva to include patients with multiple myeloma.

  • Reuters23 days ago

    European Medicines Agency to review Sanofi-Regeneron's Dupixent, Cemiplimab

    The European Medicines Agency will review the Dupixent and Cemiplimab products being developed by drugmakers Sanofi and Regeneron, the companies said on Tuesday. They said the EMA had accepted to review ...

  • Alnylam Falls on Pfizer's Rare Disease Drug Success
    Zacks24 days ago

    Alnylam Falls on Pfizer's Rare Disease Drug Success

    Shares of Alnylam (ALNY) fall by more than 8% after Pfizer reports top-line results from the phase III study of tafamidis.

  • Edge Therapeutics Loses Edge on Failure of Late-Stage Study
    Zacks24 days ago

    Edge Therapeutics Loses Edge on Failure of Late-Stage Study

    Edge Therapeutics (EDGE) plummeted significantly after the company announced discontinuation of the pivotal late stage study on lead candidate.